Peptide regulation is not a single global standard. A product that is an approved medicine in one jurisdiction may be an unapproved new drug, a compounding exception, a cosmetic ingredient, or a monitored substance in another. The differences matter for anyone reading international claims.
This article compares four regulatory frameworks—the United States, the European Union and EEA, the United Kingdom, and Canada—as documented in the atlas. Each represents a distinct statutory structure, enforcement philosophy, and approach to unapproved "research peptide" products.
United States: FDA authority and compounding pathways
The US regulation page describes a system centred on the Food and Drug Administration under the Federal Food, Drug, and Cosmetic Act. Approved peptide drugs include GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, and others), insulin analogues, GnRH analogues, somatostatin analogues, and several additional therapeutic peptides. Each approval is specific to a product, formulation, route, and indication.
Unapproved peptides sold for human use are unapproved new drugs. Labelling a product "for research use only" does not exempt it from the FDCA if the seller knows or should know it is intended for human use—FDA has issued numerous warning letters under this theory.
Compounding operates under two pathways. Section 503A covers traditional, patient-specific compounding in registered pharmacies. Section 503B covers outsourcing facilities that voluntarily register with FDA and comply with CGMP. In May 2026, FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, a preliminary finding that does not decide every lawful-compounding question but signals heightened scrutiny on GLP-1 compounding.
European Union and EEA: centralised medicines, decentralised enforcement
The EU/EEA regulation page shows a different architecture. The European Medicines Agency evaluates centrally authorised peptide drugs through Regulation (EC) 726/2004, while individual member states authorise others through mutual recognition or decentralised procedures. Biologically derived peptides (rDNA production) must use the centralised pathway; chemically synthesised peptides may choose among several routes.
Pharmacy compounding is a member-state competence, not harmonised at EU level. Directive 2001/83/EC exempts magistral and officinal formulae from marketing authorisation, but the Court of Justice clarified in the Abcur judgement (C-544/13 and C-545/13) that stock preparation for unspecified patients is industrial manufacture, not compounding. Germany, France, and the Netherlands have developed pharmacy preparation sectors; others restrict compounding to extemporaneous only.
No specific EU-level exemption exists for "research chemicals." If a product meets the medicinal product definition through its claims, it requires a marketing authorisation. Enforcement varies widely by member state.
The EU Cosmetics Regulation (EC) 1223/2009 covers peptide ingredients in cosmetic products, and Regulation (EU) 2015/2283 covers novel foods—a peptide could fall into multiple categories depending on claims and intended use.
United Kingdom: post-Brexit regulation and active enforcement
The UK regulation page documents the standalone post-Brexit system under the Human Medicines Regulations 2012. The MHRA is the single regulator. Licensed peptide-class medicines include semaglutide, tirzepatide, insulin analogues, teriparatide, leuprorelin, and others—all prescription-only.
Compounding operates through Section 10 of the Medicines Act 1968 for patient-specific pharmacy preparation, and through the "Specials" regime (Regulation 167 of HMR 2012) for unlicensed products manufactured to a prescriber's specification when no suitable licensed alternative exists.
The UK is distinctive for the explicitness of its enforcement. In April 2026, the MHRA announced an investigation into peptide clinics making unverified medicinal claims. The MHRA Borderlines lead stated that claims of "research purposes" are disregarded when promotional material, usage guidance, and FAQ content make clear the product is aimed at human use. The GPhC issued a fitness-to-practise warning in January 2026 to a pharmacist who imported unlicensed prescription-only medicines from China.
Canada: no "research use" exemption
The Canada regulation page shows a system built on the Food and Drugs Act. Peptides are classified as drugs, natural health products, or food ingredients based on composition, intended use, and claims. Approved peptides include GLP-1 agonists, insulin, teriparatide, leuprolide, and others—each with a Drug Identification Number.
No statutory "research use only" exemption exists. The Minister has exemption power under section 30.05, but it is not routinely exercised for individual peptide products. Canada Border Services Agency routinely seizes shipments of unapproved peptides destined for consumers. Health Canada has taken action against clinics promoting peptide therapies.
The compounding policy (POL-0051) distinguishes manufacturing from compounding, and most peptide raw materials from "research chemical" channels do not meet compendial-grade quality expectations for compounding. Sterile compounding must comply with CSA standard Z314.8, enforced by provincial pharmacy authorities.
What the comparison shows
Each framework reaches the same practical conclusion for unapproved peptides marketed for human use—they are not legally marketable as medicines—but through different statutory paths, exemption structures, and enforcement intensities. The US relies on the FDCA intended-use test and compounding pathways. The EU operates through centralised evaluation with variable member-state enforcement. The UK has been notably explicit in its enforcement stance. Canada applies its Food and Drugs Act with no research-use loophole.
A product's regulatory status therefore depends on jurisdiction, claims, composition, and intended use—not on its label wording alone. For the detailed rules, evidence, and enforcement records in each jurisdiction, consult the individual regulation pages linked above.
For an explanation of how regulatory status is incorporated into evidence grades across the atlas, see the scope and selection methodology.